Miltown

Quick links to important sections

Miltown

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miltown

Quick Facts

Property Description
Active Ingredient Meprobamate
Form Tablet or Capsule (Oral)
Pharmacological Class Anxiolytic / Sedative-Hypnotic
General Purpose Relieving tension and anxiety
Origin Synthetic Compound

What Type of Drug is Miltown?

Miltown is the legacy trade name for the drug containing the active substance Meprobamate, which is classified as a miscellaneous anxiolytic and sedative-hypnotic agent. Meprobamate holds unique historical significance as the first major tranquilizer, its introduction in 1955 having profoundly influenced the pharmacological approach to anxiety management. Pharmacologically, Meprobamate is defined as a carbamate derivative, a distinct chemical family from the later developed benzodiazepines, though both exert their effects by depressing the central nervous system. Its role as a pioneering compound is recognized for its historical role in pharmacology.

Composition, Origin, and Forms of Meprobamate

The active ingredient is Meprobamate, a purely synthetic compound manufactured through chemical synthesis rather than being naturally derived. As a single-ingredient product in its original formulation, the drug’s properties are solely attributed to this molecule. Meprobamate is typically provided for oral administration in solid dosage forms, supplied as a compressed tablet or contained within a capsule. This established oral route confirms the medicine is designed for systemic action rather than local effect.

General Purpose and Core Action of this Tranquilizer

The general purpose of Miltown is to induce a state of tranquility and help relieve feelings of elevated tension and generalized anxiety. For instance, a typical use involves addressing generalized restlessness or muscle tension associated with psychosomatic conditions. Meprobamate achieves this through its primary action as a central nervous system (CNS) depressant, which is noted for its ability to quiet overactive nerve signaling. Furthermore, Meprobamate possesses a unique, centrally acting skeletal muscle relaxant property by interrupting specific interneuronal communication, contributing to its ability to soothe both emotional distress and physical manifestations of stress.

What side effects are possible with Miltown?

Possible Side Effects and Safety Information

The official safety profile for Meprobamate, the active ingredient in Miltown, categorizes adverse reactions primarily by their frequency and the system-organ class affected. Reactions common in regulatory documents are generally related to its CNS depressant activity, including drowsiness and ataxia (clumsiness or unsteadiness).

However, the label also documents rare, serious, and potentially life-threatening adverse reactions. These severe issues include blood disorders such as aplastic anemia and agranulocytosis, as well as severe idiosyncratic skin reactions like Stevens-Johnson syndrome and anaphylaxis. These serious events often affect the Blood and Lymphatic System Disorders and the Skin and Subcutaneous Tissue Disorders as documented in official regulatory classifications.

Time- and exposure-related patterns are noted in the safety profile. Acute idiosyncratic reactions, such as fever or rash, often appear rapidly, frequently within the first few doses of treatment. In contrast, the potential for physical and psychological dependence is associated with long-term exposure, and abrupt cessation after prolonged use may lead to severe withdrawal syndromes, including delirium and seizures.

Safety limitations are defined for certain populations and pre-existing conditions. Official labeling advises caution for older adults due to increased sensitivity and a higher risk of confusion or falls. The medicine is formally contraindicated in patients with acute intermittent porphyria or known hypersensitivity to meprobamate or related compounds. Furthermore, the product information indicates that Meprobamate may impair the mental and physical abilities necessary for performing hazardous tasks like driving or operating machinery.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Miltown (Meprobamate) overdose is dominated by the risk of severe Central Nervous System (CNS) and cardiorespiratory depression. Documented clinical manifestations range from severe confusion, slurred speech, uncoordinated movement (ataxia), and deep drowsiness to stupor and coma.

The physiological impact often includes profound hypotension, tachycardia or bradycardia, and the critical potential for respiratory arrest. Life-threatening outcomes documented in official labeling include vasomotor collapse, circulatory shock, and death.

A key regulatory constraint is the additive effect when Meprobamate is co-ingested with alcohol or other CNS depressants, which substantially increases the risk of a fatal outcome. Furthermore, elderly patients and those with existing kidney or liver impairment may face increased severity due to slower drug clearance.

In all cases of suspected overdose, the official guidance is to seek immediate medical attention and get emergency help at once. Management is purely symptomatic and supportive, as no specific antidote is known. Procedures documented in regulatory texts for severe overexposure may include methods for drug removal, such as gastric lavage or specialized techniques like hemodialysis.

Therapeutic Uses of Miltown

Miltown (Meprobamate) may be part of symptomatic management for conditions involving nervous tension and is relevant in contexts marked by increased discomfort or tension. The medication is used in areas where short-term symptom management is appropriate, and generally supports the patient during difficult episodes by easing distress.

The medication is commonly used to help manage symptom clusters that may become intense or disruptive, particularly those related to excessive nervous tension, generalized restlessness, and stress-related physical tension.

Symptomatic Domains and Core Benefit

Meprobamate is primarily applied in addressing symptom clusters that may become intense or disruptive, such as pervasive worry and elevated psychological tension. The drug is also considered relevant in contexts marked by increased discomfort due to its effect on reducing physical tension, helping to ease symptoms of increased neurological or muscular activity. This supports patients by providing supportive relief when symptoms interfere with routine activities.

Used in situations where patients experience heightened distress, the medication contributes to easing the overall symptom load during periods of symptomatic discomfort.

Quick Fact: Relief for Tension and Anxiety
Therapeutic Focus: Relevant for short-term symptomatic relief of tension and anxiety.
Symptom Benefit: Supports the management of both psychological tension and physical restlessness.
Context: Relevant in situations requiring temporary assistance in symptom stabilization.

Regulatory References

  1. NIH DailyMed Meprobamate Label

Eligibility and Restrictions for Use

Who can and cannot use Miltown? — Official Regulatory Information

Regulatory documents define specific populations who are prohibited from using Miltown (Meprobamate) and groups for whom use is restricted or conditional.

Contraindicated/Prohibited Use Population/Condition Requiring Restriction
Acute Intermittent Porphyria Compromised Liver or Kidney Function
Hypersensitivity/Allergy to Meprobamate or related carbamate compounds (e.g., carisoprodol) Elderly and/or Debilitated Patients (use lowest effective dose)
First Trimester of Pregnancy (use should almost always be avoided) Children under 6 years of age (safety and effectiveness not established)

Use is contraindicated in patients with a history of acute intermittent porphyria or known allergic reactions to meprobamate or its chemical relatives. The medication is not recommended for use in children under six years of age due to a lack of established safety and effectiveness data.

For pregnant women, use during the first trimester is generally avoided due to a suggested increased risk of congenital malformations. Meprobamate is also present in breast milk at high concentrations, a factor that must be considered when use is contemplated in nursing patients.

Caution is required for patients with compromised liver or kidney function to prevent drug accumulation, and the lowest effective dose must be administered to elderly patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns based strictly on government regulatory documentation. Miltown (Meprobamate) is subject to both formal contraindications and pharmacodynamic interactions.


Formal Regulatory Restrictions

Co-administration is contraindicated in patients with a history of Acute Intermittent Porphyria. Use is also contraindicated if a patient has experienced a known hypersensitivity or idiosyncratic reaction to Meprobamate or any related carbamate derivative, such as carisoprodol.


Pharmacodynamic and Substance Interactions

The most significant interaction is the additive central nervous system (CNS) depressant effect. This occurs when Meprobamate is co-administered with alcohol (ethanol) or other substances that depress the CNS. The list of potentially interacting agents includes opioid analgesics, sedative-hypnotics, certain antidepressants, antihistamines, and general anesthetics.


Exposure and Clearance Considerations

Caution is formally required for patients with compromised liver or kidney function. Because the drug is cleared via hepatic metabolism and renal excretion, these conditions increase the risk of excess accumulation in the body. Additionally, regulatory information notes that agents classified as CYP2C19 inhibitors or inducers, as well as the herbal product St. John's Wort, can alter Meprobamate exposure (as a metabolite of carisoprodol).

Mechanism of Action

Modulation of the Central Inhibitory System

The mechanism involves modulating the brain's primary inhibitory pathway, the mathbfgamma-Aminobutyric acid type A (mathbfGABAmathbfA) receptor system. Meprobamate acts as a positive allosteric modulator, enhancing the receptor's activity and increasing the influx of inhibitory chloride ions ( Cl^-) into neurons. This action results in the hyperpolarization of nerve cells, causing a widespread dampening of signaling across critical CNS structures like the limbic system and reticular formation.


Interruption of Spinal Motor Reflexes

Beyond its widespread central effects, the drug exhibits a distinct, targeted mechanism by selectively interrupting communication at interneurons located in the spinal cord and subcortical areas. By blocking signal transmission within these polysynaptic motor reflex arcs, Meprobamate modifies the feedback loops that regulate muscle tone. This specific action on motor pathways produces the physiological consequence of a reduction of skeletal muscle tone.


Resulting Physiological Effects and Limitations

The convergence of enhanced CNS inhibition and motor pathway modulation produces a physiological state of reduced arousal and reduction of motor outflow. However, this persistent alteration of the GABAmathbfA system triggers a biological constraint known as neuroadaptation, where the target cells adjust to the drug's influence, leading to a diminished physiological response over time.

Dosage and Administration Information

Miltown (meprobamate) is taken orally and must be used strictly as directed by a healthcare provider. The lowest effective dose should be administered, particularly for elderly or debilitated patients.

Official Dosing and Administration

Population Dosage (Regular Tablet) Frequency
Adults (≥12 years) 1200 mg to 1600 mg daily (e.g., 400 mg) In three or four divided doses (maximum 2400 mg/day)
Children (6–12 years) 200 mg to 600 mg daily (e.g., 100 mg to 200 mg) In two or three divided doses

For extended-release forms, the dosage for adults and children 12 years and older is typically 400 mg to 800 mg taken two times a day. Dosing for children under six years of age must be determined by the prescriber. The medicine is not explicitly required to be taken with or without food.

Procedural and Course Instructions

  • Missed Dose: If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, the missed dose should be skipped to prevent doubling the amount taken.
  • Duration and Review: The effectiveness of meprobamate in long-term use, defined as more than four months, has not been systematically assessed, and the healthcare provider should periodically reassess the continued need for the drug.
  • Discontinuation: The medication should not be stopped suddenly after prolonged use. The dosage must be reduced gradually over one to two weeks, as directed by a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Miltown


Evidence for Short-Term Relief of Anxiety and Nervous Tension

Meprobamate was evaluated in research examining symptoms of anxiety disorders and general nervous tension. The evidence base includes early, short-term controlled studies conducted during the mid-20th century. These original studies compared Miltown to either an inactive substance (placebo) or other older sedative agents. Researchers focused on outcomes related to systemic or functional imbalance by monitoring changes recorded on specialized anxiety rating scales and patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies related to measures of calming/tranquilizing response and changes measured during the study period, particularly a reduction in measures of restlessness and physical tension. This research provides insight into short-term changes observed in the specific adult populations studied.


Evidence for Management of Tension Associated with Musculoskeletal Conditions

Miltown was also evaluated in research exploring its role as an adjunct for managing muscle tension, especially in conditions characterized by fluctuating or episodic manifestations of musculoskeletal pain. Research examining this indication frequently involved combination products where Meprobamate was often paired with an analgesic. Studies reported how symptoms evolved in the observed populations, and findings indicate patterns related to overall changes in symptoms assessed in subjects dealing with both pain and associated physical tension.


Long-Term Data and Follow-Up Duration

The research record for Miltown is predominantly characterized by short-term follow-up durations. According to regulatory findings, there is limited information for long-term outcomes regarding sustained use. Research observing the effectiveness of the drug in continuous long-term use (i.e., beyond four months) has not been systematically conducted, as noted in regulatory records.


Key Uncertainties and Evidence Gaps

Key limitations in the evidence landscape stem from the drug's historical origin; the evidence quality varies across studies, and many of the early trials do not meet the stringent standards of contemporary research. The sample sizes were modest in many early studies, and follow-up durations were limited, restricting the ability to draw conclusions about long-term outcomes. Additionally, there is limited information comparing Miltown against modern pharmacological treatments.

Key Studies & References

  1. Meprobamate Tablets - DailyMed (Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Miltown (FAQ)


Q: Do you get withdrawal symptoms if you stop taking Miltown suddenly?

Yes, official regulatory documents warn that abruptly stopping Miltown after prolonged use can lead to severe withdrawal syndromes. These symptoms can be serious and may include agitation, delirium, and seizures. This is why official guidance advises that the dosage be reduced gradually, as directed by a healthcare professional, rather than stopping suddenly.


Q: What are the serious, but rare, side effects of Miltown?

While rare, regulatory sources document potentially life-threatening side effects. These include serious blood disorders like aplastic anemia and agranulocytosis (a severe drop in white blood cell count). Severe, acute reactions affecting the skin, such as Stevens-Johnson syndrome and anaphylaxis (a severe allergic reaction), have also been reported.


Q: Can Miltown interact with herbal supplements like St. John's Wort?

Official information indicates caution is needed. Regulatory notes state that the herbal product St. John's Wort can potentially alter the amount of meprobamate in the body, which is a metabolite of a related drug (carisoprodol). It is important for patients to discuss all supplements being taken with a healthcare provider.


Q: Is Miltown affected by eating certain foods, like grapefruit?

Official prescribing information does not explicitly require Miltown to be taken with or without food. While some medicines have known issues with specific foods like grapefruit, such an interaction is not formally listed in the provided regulatory documents for Miltown.


Q: Can Miltown be used to help with general stress or only diagnosed anxiety?

Miltown is officially indicated for the management of anxiety disorders or for the short-term relief of significant anxiety symptoms. According to regulatory guidance, the anxiety or tension associated with the stress of everyday life usually does not require treatment with this type of anxiolytic medication.


Q: Does Miltown make anxiety worse when you try to stop taking it?

Stopping the drug suddenly after a long period of use can cause a withdrawal syndrome. This withdrawal may include symptoms of increased nervousness or anxiety. This reaction is primarily a result of the body’s physical dependence on the medication.


Q: Can Miltown cause problems with memory or concentration?

Official warnings state that Miltown may impair the mental and physical abilities required for performing tasks that require focus, such as driving or operating machinery. Side effects like confusion and slurred speech are noted, which suggests a potential impact on clear thinking and concentration.


Q: What should someone do if they miss a dose of Miltown?

Official guidance provides specific instructions for managing a missed dose. This typically advises patients to consult their medication guide regarding the time elapsed since the missed dose and whether to take it or skip it to avoid taking too much medication.


Q: What are the signs of taking too much Miltown?

Symptoms of taking too much Miltown (overdose) can include severe effects on the central nervous system. Regulatory information lists signs such as severe drowsiness or confusion, loss of muscle coordination, slurred speech, a severely slow heartbeat, and slow or troubled breathing.


Q: How long does Miltown stay in your system after taking a dose?

Pharmacokinetic data indicates that meprobamate, the active ingredient, has a plasma half-life of approximately 10 hours, though this can vary. The drug is processed by the liver and eliminated primarily through the kidneys.


Q: How long does Miltown take to start working for anxiety?

Miltown is well-absorbed after it is taken orally. Official data suggests that the sedative and calming effects are generally reported to begin within approximately 1 hour after taking a dose.


Q: What does Miltown feel like when it kicks in?

When the medication starts to work, common effects are related to its action as a central nervous system depressant. Patients commonly report feeling drowsiness or a sense of unsteadiness. Some people may also experience a calming effect or a false sense of well-being (euphoria).


Q: Is Miltown the same kind of drug as a modern antidepressant?

No, Miltown is not classified as a modern antidepressant. Official sources classify Miltown (meprobamate) as a miscellaneous anxiolytic and a sedative-hypnotic agent. Its primary action is to depress the central nervous system to relieve anxiety and tension.


Q: Is Miltown highly addictive compared to other older sedatives?

Miltown is classified as a Schedule IV controlled substance. This designation indicates that the drug has an accepted medical use but also carries a recognized risk for abuse and potential for both psychological and physical dependence.


Q: What happens if you take Miltown and drink a lot of coffee?

Miltown is a central nervous system (CNS) depressant. While a direct interaction with coffee is not formally listed in regulatory documents, the stimulant effects of caffeine may counteract the desired sedative effects of the medication.


Q: Is Miltown ever used for insomnia or trouble sleeping?

Miltown is classified as a sedative-hypnotic. Although its primary indication is anxiety and tension, due to its depressant effects on the central nervous system, it has been used for the short-term management of difficulty sleeping (insomnia).


Q: Why was Miltown eventually replaced by benzodiazepines?

Miltown was eventually superseded by benzodiazepines, a newer class of drugs with a different chemical structure. The transition was driven by growing concerns over Miltown’s potential for dependence and its safety profile regarding overdose risk, leading to its replacement by the chemically distinct benzodiazepines.


Q: Is Miltown commonly used in children?

Official labeling indicates that Meprobamate is conditionally indicated for use in children ages 6 to 12 for selected conditions. However, the drug is explicitly not recommended for children younger than six years old because its safety and effectiveness have not been established in that age group.


Q: Does Miltown have a generic version available?

Yes, Miltown is the brand name for the generic drug Meprobamate. Regulatory documents confirm that generic meprobamate tablets are available as a therapeutic option.


Q: Is it normal to feel a bit 'out of it' when first starting Miltown?

Yes, it can be normal to feel less alert at the start of treatment. Common side effects include drowsiness, dizziness, and ataxia (a lack of muscle coordination). These effects are related to the drug's action on the central nervous system and may be more noticeable initially.


Q: Can Miltown be detected on standard drug tests?

Yes, meprobamate is classified as a Schedule IV controlled substance by the U.S. government. As a result, it can be detected in specific drug tests that specifically screen for a panel of controlled substances.


Q: What kind of research evidence supports Miltown's use for anxiety?

Studies supporting Miltown’s use are mainly from early, short-term controlled trials. These studies indicated a calming effect and a reduction in measures of restlessness and physical tension when compared to a placebo or other older sedative agents.


Q: Is there a risk of Miltown causing rebound anxiety?

When Miltown is stopped, the body experiences withdrawal symptoms as a result of physical dependence. These symptoms can include an increase in anxiety and nervousness, which may be perceived as rebound anxiety.


Q: Can Miltown cause dizziness or unsteadiness?

Yes, official safety information documents that dizziness is a common side effect of Miltown. Ataxia, which is described as a lack of muscle coordination, clumsiness, or unsteadiness, is also a frequently reported adverse reaction.

How should Miltown be stored and disposed of?

Storage and Handling Requirements

Miltown (meprobamate) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with thermal excursions permitted between 15 C and 30 C (59 F and 86 F).

Storage Mandates
Temperature Controlled Room Temperature: 20 C–25 C
Container Preserve in a well-closed container with a child-resistant closure
Protection Keep strictly out of reach of children

Official Disposal Instructions

As specified by regulatory guidance, the preferred method for discarding unused Miltown is through drug take-back programs. If a take-back option is not readily available, the product can be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a container before disposal in the household trash. Meprobamate is not listed as a drug recommended for immediate flushing, meaning it must not be poured down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Miltown found in:

A-Z Index: